143results about "Group 7/17 element organic compounds" patented technology

The present invention belongs to the technical field of radiopharmaceutical chemistry and nuclear medicine diagnosis and treatment and relates to a radiolabeled FAPI complex, a preparation method therefor, and a use thereof. The general structural formula of FAPI capable of realizing radionuclide labeling is as shown below: wherein R is a nitroimidazole group or -COOH; X is a chelating group or a chelating structure chelated with a radionuclide; L1 and L2 are linking groups; and A is an adjusting atom of an FAP-targeting group, and all the A atoms are H atoms or F atoms. The synthesis method for a radionuclide-labeled precursor of the present invention is simple and suitable for various nuclide labels, the labeling method is convenient, and the label has high radiochemical purity and good stability. The radiolabeled FAPI complex shows high affinity and specificity for FAP in a cell experiment and a high tumor uptake and target to non-target ratio in a tumor-bearing mouse, and is a potential FAP-targeting radioactive diagnosis and treatment drug.

The disclosure relates to double halogenated phenylalanine derivatives, which can be radiolabeled with PET or SPECT radioisotopes, and their use in treating and / or imaging cancer.

The invention relates to a 2N type manganese complex and a preparation method thereof, and a preparation method of phenylalkyl disiloxane. The invention discloses a 2N-type manganese complex and a preparation method thereof, and the preparation method comprises the following steps: (1) adding 2-bromo-pyridine, a ligand, potassium carbonate and cuprous iodide into a dimethyl sulfoxide solution, and reacting at 110-130 DEG C for 20-28 hours to obtain an N, N bidentate ligand; the ligand is 1-(pyridine-2-yl)-1H-indole, or 2-(1H-pyrazole-1-yl) pyridine, or 2-(2H-1, 2, 3-triazole-2-yl) pyridine, and the ligand is one or more of 1-(pyridine-2-yl)-1H-indole, 2-(1H-pyrazole-1-yl) pyridine, 2-(2H-1, 2 And (2) dissolving the N, N bidentate ligand and Mn (CO) 5Br in a tetrahydrofuran solution, and reacting at 65-75 DEG C for 10-14 hours to obtain the 2N type manganese complex. According to the 2N-type manganese complex, the preparation method thereof and the preparation method of the phenyl alkyl disiloxane, the 2N-type manganese complex is used as a catalyst for hydrosilylation reaction of pentamethyldisiloxane, styrene and derivatives thereof to prepare the phenyl alkyl disiloxane.

The invention discloses a bimetallic asymmetric reduction Schiff base catalyst for synthesizing ethylene carbonate and a preparation method of the bimetallic asymmetric reduction Schiff base catalyst. According to the catalyst, a diamine compound is subjected to selective single-side protection, the imine reduction position is controlled, and a bimetallic active center is introduced; the controllable synthesis of a product for reducing the outer side imine and a product for reducing the inner side imine is realized; the obtained product is recrystallized to obtain a monoimine-monoamine type ligand with a clear asymmetric structure, the monoimine-monoamine type ligand and metal salt form a bimetallic catalyst, and the catalyst generates a synergistic effect through double active sites and shows high catalytic activity and excellent product selectivity.

The invention relates to a photoactivated carbonyl manganese (I) complex and a preparation method and application thereof in antibiosis. The manganese (I) complex has a good photoactivation antibacterial effect. Specifically, the manganese carbonyl (I) complex can be photoactivated to release carbon monoxide and ligands under the irradiation of white light. By detecting MIC90 of the photoactivated carbonyl manganese (I) complex to different bacteria, the result shows that the photoactivated carbonyl manganese (I) complex has a better antibacterial effect on mycobacterium smegmatis.

The invention relates to a non-gadolinium magnetic resonance contrast agent and a preparation method thereof, and belongs to the field of contrast agents. The invention aims to provide a non-gadolinium contrast agent with high biological safety aiming at the risks of renal fibrosis and cerebral deposition existing in a gadolinium-based magnetic resonance contrast agent. The invention provides a phosphate group modified non-gadolinium magnetic resonance contrast agent. The phosphate group modified non-gadolinium magnetic resonance contrast agent consists of a ligand of a phosphate group substituted trans-cyclohexanediamine tetraacetic acid derivative (tmPCDTA or tqPCDTA) and metal ions Fe < 3 + > or Mn < 2 + >, the contrast agent disclosed by the invention is high in biological safety: endogenous Fe < 3 + > / Mn < 2 + > is used for replacing gadolinium, and cell experiments prove that the survival rate of 4T1 cells is not influenced at the concentration of 500 mu M; clinical applicability is high, kidney excretion is rapid, bladder signals are enhanced 3-5 minutes after mouse intravenous injection, and liver retention is avoided.

The present invention provides radiolabeled tyrosine derivatives that have excellent LAT1 selectivity, have higher retention at tumor or cancer sites, and have a level of clearance that does not cause side effects, and that can be produced stably with good purity by a safe method suitable for industrial production. The present invention provides a radiolabeled compound represented by Formula (I) or a pharmaceutically acceptable salt thereof: wherein each symbol is as defined in the present specification.

The invention discloses preparation and application of a Salen metal complex material containing imidazolyl ionic liquid and a pyridine ring (MVIM-Salen), and belongs to the technical field of synthesis of ionic liquid metal complex catalytic materials. According to the method, salicylaldehyde containing imidazolyl ionic liquid and 2, 3-diaminopyridine are subjected to an ammonia-aldehyde condensation reaction to construct a Salen structure, a VIM-Salen complex (MVIM-Salen) material containing metal active sites is prepared through metal coordination, and the MVIM-Salen material has ionic liquid, halogen anions and metal active sites and is used for synthesizing dimethyl carbonate (DMC) through concerted catalysis of CO2. The MVIM-Salen catalytic material has the advantages of multiple active sites, uniform distribution, better stability, simple synthesis process, low synthesis cost, green and environment-friendly synthesis process and the like. The prepared MVIM-Salen catalytic material is applied to synthesis of DMC from CO2, and shows excellent catalytic performance under relatively mild reaction conditions.

The present invention relates to a marked fatty acid derivative, a precursor compound thereof, and use thereof in a contrast agent. The derivative is represented by formula I: wherein M is 99mTc or Re; R, R1, R2, R3, R4 and R5, and A1-A12 are independently H, an aliphatic chain or an alicyclic; J, X, and Y are independently absent, or -O-, -S- or (II), and J, X, and Y are not simultaneously absent; R6-R14 are independently H or an aliphatic chain, and R13 and R14 are not H simultaneously; z is 1-6, a is 0-5, b is 0-5, and c is 0-3; d is 0-27, e is 0-27, f is 0-28, g is 0-7, and at least two of d, e, f and g are not 0. The present invention provides a completely novel structure type that can be used for preparing a novel myocardial metabolism contrast agent, possessing important clinical application prospects.

A method is provided for manufacturing an aqueous formulation of a manganese-containing coordination complex, by combining a source of the manganese-containing coordination complex with a source of chloride anion in an aqueous solution, and simultaneously with or following combination of the source of chloride anion and the source of manganese-containing coordination complex in the aqueous solution, providing a source of a dianion to the aqueous solution to form the aqueous formulation.

Provided is a novel photothermal conversion material. A manganese oxide cluster compound represented by general formula (1). (In general formula (1), L is a tricarboxytriptycene residue, alpha1 is an organic acid residue, beta1 is a solvent selected from the group consisting of water and a polar organic solvent having a dielectric constant of 6-47, P1 is a coordinating molecule selected from the group consisting of a nitrogen-containing heterocyclic compound, an oxygen-containing cyclic compound and a phosphine, or a polymer containing the coordinating molecule, [gamma] 1 is a solvent selected from water and a polar organic solvent having a dielectric constant of 6-47, q is a number of 0 < = m < = 8, and m is a number of 0 < = m < = 10. ).

Provided is a method by which a stably radiolabeled tyrosine derivative having a good purity can be produced in a safe manner suitable for the industrial production of pharmaceuticals.　The present invention pertains to a method for producing compound (5) and radiolabeled compound (6). [In the formulae, each symbol is as defined in the description.]

A luminescent material is a complex with the following structural formula: wherein R and R' are independently selected from oxygen, amino, C1-C18 straight-chain or branched alkyl-substituted amino, phosphin, C1-C18 straight-chain or branched alkyl-substituted phosphin, sulfur, and selenium; R1, R2, R3, R4, R5, and R6 are independently selected from hydrogen, C1-C18 straight-chain or branched alkyl or halogen-substituted C1-C18 straight-chain or branched alkyl, aromatic... Aromatic groups such as benzene, thiophene, and furan, n = 1–3, are used to construct cyclic ligand skeletons with different half-ring numbers. Ln is one of the following: cerium trivalent ion, europium divalent ion, ytterbium divalent ion, and samarium divalent ion. M is one of the following: manganese divalent ion, cobalt trivalent ion, chromium trivalent ion, vanadium trivalent ion, and ferric trivalent ion. X is a monovalent ion, such as halogen, cyanide, thiocyanate, isothiocyanate, etc., m = 0–3, l = 3–6. X acts as a monodentate ligand or as a bridging bidentate ligand.

To provide a metal complex which is useful for producing a negative electrode active material having superior initial coulombic efficiency and capacity retention and a method for producing the same, a negative electrode active material precursor containing the metal complex and a method for producing the same, a negative electrode active material, and a secondary battery having the negative electrode active material.SOLUTION: A metal complex contains a metal cation, the counterion of which includes a carboxylate anion having 2-20 carbon atoms and having a protected amino group.SELECTED DRAWING: None

The invention belongs to the technical field of magnetic refrigeration materials, and particularly relates to manganese pentaethylenehexamine hydrochloride and a preparation method and extremely low temperature magnetic refrigeration application thereof. The chemical formula of the extremely low temperature magnetic refrigeration material is [Mn (C10H28N6)] Cl2; the magnetic phase transition temperature of the extremely-low-temperature magnetic refrigeration material is lower than 0.4 K. The extremely-low-temperature magnetic refrigeration material has a large magnetothermal effect near 1K, and when the magnetic field change is 0-5T, the maximum magnetic entropy change is smaller than or equal to 40.8 J * kg <-1 > * K <-1 >. The extremely-low-temperature magnetic refrigeration material is rich in preparation raw materials, simple in process, free of rare earth elements, low in cost and suitable for industrial large-scale production.

To provide a compound including ligands improving device performance.SOLUTION: For example, provided herein is an Ir complex compound with 2-phenylpyridine ligands with specific substituents on the pyridine rings, which is prepared as the formula in the figure.SELECTED DRAWING: Figure 1

The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof (Formula I), wherein each of R<supgt;1< / supgt> - R<supgt;30< / supgt> is independently selected from the group consisting of H and deuterium, and at least one of R<supgt;1< / supgt> - R<supgt;30< / supgt> is deuterium having an abundance level greater than the natural abundance of deuterium. The present invention also provides a pharmaceutical composition containing the compound and the use of the compound.

To provide a method for preparing an in situ metal doped manganese iron oxalate precursor.SOLUTION: Iron source, manganese source, doped metal elements (Mg, Zn, etc.) are weighed according to a stoichiometric ratio, and deionized water is added to the weighed metal to ultrasonically dissolve the weighed metal to obtain a mixed metal solution. The mixed metal solution is added to a prepared oxalic acid solution and subsequently a certain concentration of complexing agent is added to the solution to perform co-precipitation reaction under the protection of inert gas. A resultant suspension of metal doped manganese iron oxalate is recovered and then filtered, washed and dried to obtain a powder of manganese iron oxalate precursor.EFFECT: By using the manganese iron oxalate precursor as the iron and manganese sources, this can effectively avoid the problem of uneven mixing due to the iron and manganese sources. Moreover, lithium manganese iron phosphate synthesized from the manganese iron oxalate precursor after metal doping can significantly improve the electronic conductivity, thereby enhancing the electrochemical properties of lithium manganese iron phosphate.SELECTED DRAWING: Figure 1

The present application relates to an intermediate of fulvestrant and a preparation method thereof. Specifically, the present application relates to a compound as shown in formula V and a preparation method thereof, wherein R 1 is hydrogen or a hydroxyl protecting group. The present application also relates to a preparation method for synthesizing fulvestrant via the compound as shown in formula V, which has the advantages of short reaction steps, mild and safe reaction conditions, high selectivity, simple operation and purification, high synthesis efficiency, and is suitable for large-scale production.

The invention relates to hybrid polymer / filler materials prepared from bipyridine derivatives functionalised with acrylate groups of formula (I) and / or metal complexes comprising said functionalised bipyridine derivatives, wherein the polymer comprising the functionalised bipyridines can form a shell around the filler, as well as to the method for preparing same and the uses thereof.

The invention relates to a fulvestrant intermediate and a preparation method thereof. Specifically, the invention relates to a compound shown as a formula V and a preparation method thereof, and R1 is hydrogen or a hydroxyl protecting group. The invention also relates to a preparation method for the synthesis of fulvestrant from the compound as shown in the formula V. The method has the advantages of short reaction steps, mild and safe reaction conditions, high selectivity, simplicity and convenience in operation and purification, high synthesis efficiency and the like, and is suitable for large-scale production.

The present invention discloses an inorganic-organic hybrid carbonyl radical luminescent material, its preparation method and application, belonging to the technical field of luminescent materials. In the inorganic-organic hybrid carbonyl radical luminescent material provided by the present invention, the common feature is that the tris-carbonyl substituted benzene derivative molecule after weak coordination with metal is used as the guest, and a series of imidazolium salt ionic liquid molecules are used as the host, and a supramolecular assembly is formed by the way of host-guest doping; the electrostatic interaction and electron delocalization effect generated in the system protect the carbonyl radical to emit stable light; the metal ions coordinated with the radical molecules in the assembly regulate the photophysical properties of the inorganic-organic hybrid carbonyl radical luminescent material through charge transfer. The synergistic effect of the three components enables the inorganic-organic hybrid carbonyl radical luminescent material of this type to obtain the property of adjustable emission color and realize the dual-mode detection of Cd<supgt;3+< / supgt; (turn off type) and Pb<supgt;3+< / supgt; (turn on type).

The invention discloses an organic light-emitting material containing a cycloalkyl auxiliary ligand, which is realized by providing a metal complex and adopts a series of novel cycloalkyl-containing acetylacetone auxiliary ligands. The metal complex containing the novel cycloalkyl structure-containing auxiliary ligand can be used as a luminescent material in a luminescent layer of an organic electroluminescent device. The novel ligands can effectively prolong the service life of the device, change the sublimation characteristic and improve the performance of the device. An electroluminescent device and a compound formulation are also disclosed.

The present invention relates to new manganese (Mn2+) chelate compounds, to methods of preparing said compounds, to the use of said compounds as contrast agents in diagnostic imaging such as magnetic resonance imaging (MRI) and to their use in a mammalian body.